Asimenia Angelidou , MD, PhD
Physician in Medicine, Division of Newborne Medicine
Assistant Professor of Pediatrics, Harvard Medical School
Image
Asimenia Angelidou , MD, PhD
Physician in Medicine, Division of Newborne Medicine
Assistant Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Greek
Education
Medical School
University of Athens Medical School
2008
Athens
Greece
Internship
Pediatics
Children's Medical Center at Dallas
2012
Dallas
TX
Graduate School
PhD, Immunopharmacology
University of Athens Medical School
2013
Athens
Greece
Residency
Pediatrics
Children's Medical Center at Dallas
2014
Dallas
TX
Fellowship
Harvard Neonatal-Perinatal Medicine Training Program
2016
Boston
MA
Certifications
American Board of Pediatrics (General)
American Board of Pediatrics (Neonatal-Perinatal Medicine)
Professional History
Asimenia Angelidou, MD, PhD obtained her medical degree and doctoral degree in Immunopharmacology from the University of Athens in Greece. She completed her pediatric residency training at the University of Texas Southwestern and Children’s Medical Center at Dallas, TX, and her clinical fellowship in Neonatal-Perinatal Medicine at the Harvard Combined Training Program in Neonatology where she also served as Chief Fellow. She is currently an attending Neonatologist at the Boston Children’s Hospital Neonatal Intensive Care Unit and Instructor at Harvard Medical School.Dr. Angelidou has a special interest in neonatal trained immunity. Under the mentorship of Drs. Ofer Levy and Mihai Netea, she focused on newborn innate immune ontogeny and the role of vaccine-induced "heterologous protection" against unrelated pathogens, research for which she received the Marshall Klaus Perinatal Research Award from the American Academy of Pediatrics.
Approach to Care
In the Boston Children’s Hospital (BCH) Neonatal Intensive Care Unit (NICU) our philosophy is to ensure that every patient receives the best care for the best possible outcomes. We consider our “patient” to be the baby and the family; we are constantly striving to serve the needs of both. This requires a team based approach with all members being essential. The future of any society depends on its ability to foster the health and well-being of the next generation. This is the reason I chose to become a pediatrician. As a neonatologist at Boston Children’s Hospital, I am devoted to serving our smallest and most vulnerable patients by integrating highly specialized clinical care with rigorous translational science. I put great emphasis on establishing trusting relationships with families and integrating parental values in decision-making.
Publications
Safety and implementation of phase 1 randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns. View Abstract
Product and trial design considerations on the path towards a vaccine to combat opioid overdose. View Abstract
Trends in Neonatal Vaccination: A Ten-year Retrospective Study in a Large Delivery Center. View Abstract
Biomarkers of vaccine safety and efficacy in vulnerable populations: Lessons from the fourth international precision vaccines conference. View Abstract
Predictive gene expression signature diagnoses neonatal sepsis before clinical presentation. View Abstract
Safety and implementation of a phase 1 randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns. View Abstract
DNA Methylation signatures underpinning blood neutrophil to lymphocyte ratio during first week of human life. View Abstract
Breastfeeding and Neonatal Age Influence Neutrophil-Driven Ontogeny of Blood Cell Populations in the First Week of Human Life. View Abstract
Need for strategic communications and stakeholder engagement to advance acceptability of an overdose preventing vaccine targeting fentanyl. View Abstract
Proteomics-Based Mapping of Bronchopulmonary Dysplasia-Associated Changes in Noninvasively Accessible Oral Secretions. View Abstract
Precision Vaccine Adjuvants for Older Adults: A Scoping Review. View Abstract
Precision Vaccines: Lessons Learned From the Coronavirus Pandemic. View Abstract
Implications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on the Epidemiology of Pediatric Respiratory Syncytial Virus Infection. View Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus Vaccination in Pregnancy: Implications for Maternal and Infant Immunity. View Abstract
The Effects of COVID-19 Hospital Practices on Breastfeeding Initiation and Duration Postdischarge. View Abstract
Bacille Calmette-Guérin vaccine reprograms human neonatal lipid metabolism in vivo and in vitro. View Abstract
A quality improvement initiative to reduce acid-suppressing medication exposure in the NICU. View Abstract
BCG vaccine's off-target effects on allergic, inflammatory, and autoimmune diseases: Worth another shot? View Abstract
Human Newborn Monocytes Demonstrate Distinct BCG-Induced Primary and Trained Innate Cytokine Production and Metabolic Activation In Vitro. View Abstract
Leveraging the Massachusetts perinatal quality collaborative to address the COVID-19 pandemic among diverse populations. View Abstract
Association of Maternal Perinatal SARS-CoV-2 Infection With Neonatal Outcomes During the COVID-19 Pandemic in Massachusetts. View Abstract
Vaccination of Term and Preterm Infants. View Abstract
Integrative Metabolomics to Identify Molecular Signatures of Responses to Vaccines and Infections. View Abstract
Preparing for Life: Plasma Proteome Changes and Immune System Development During the First Week of Human Life. View Abstract
BCG as a Case Study for Precision Vaccine Development: Lessons From Vaccine Heterogeneity, Trained Immunity, and Immune Ontogeny. View Abstract
Licensed Bacille Calmette-Guérin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation. View Abstract
Immunometabolic approaches to prevent, detect, and treat neonatal sepsis. View Abstract
Dynamic molecular changes during the first week of human life follow a robust developmental trajectory. View Abstract
Is There More to Zika? Complex Cardiac Disease in a Case of Congenital Zika Syndrome. View Abstract
Implementation of a Guideline to Decrease Use of Acid-Suppressing Medications in the NICU. View Abstract
Neurotensin and CRH interactions augment human mast cell activation. View Abstract
Perinatal stress, brain inflammation and risk of autism-review and proposal. View Abstract
Mitochondria distinguish granule-stored from de novo synthesized tumor necrosis factor secretion in human mast cells. View Abstract
Contribution of stress to asthma worsening through mast cell activation. View Abstract
IL-9 induces VEGF secretion from human mast cells and IL-9/IL-9 receptor genes are overexpressed in atopic dermatitis. View Abstract
Mast cells in allergic and inflammatory diseases. View Abstract
Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. View Abstract
Brief report: "allergic symptoms" in children with Autism Spectrum Disorders. More than meets the eye? View Abstract
Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. View Abstract
Mast cell activation and autism. View Abstract
Mast cells and inflammation. View Abstract
Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. View Abstract
Increased affected skin gene expression and serum levels of thymic stromal lymphopoietin in atopic dermatitis. View Abstract
Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells. View Abstract
Neurotensin is increased in serum of young children with autistic disorder. View Abstract
IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. View Abstract
Locations